14 min listen
David M. Miller, MD, PhD / Kevin Emerick, MD - Coming Together to Improve Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Multidisciplinary…
David M. Miller, MD, PhD / Kevin Emerick, MD - Coming Together to Improve Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Multidisciplinary…
ratings:
Length:
14 minutes
Released:
Jan 3, 2024
Format:
Podcast episode
Description
Please visit answersincme.com/ADB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the rationale and clinical data for incorporating neoadjuvant immunotherapy into the treatment of resectable cutaneous squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating neoadjuvant immunotherapy in the treatment of resectable CSCC; Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; and Review multidisciplinary team strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.
Released:
Jan 3, 2024
Format:
Podcast episode
Titles in the series (88)
Kathleen Moore, MD, MS - Targeting Disease Progression in Advanced Ovarian Cancer: Can Combination PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes?: Please visit answersincme.com/AXF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. by CME in Minutes: Education in Oncology & Hematology